Sign inJoin waitlistJoin the waitlist

Amy Tiersten

Medical Oncology · Icahn School of Medicine at Mount Sinai

Credentials: · · · ·

History

Research

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
Journal of Clinical Oncology · 1995 · 195 citations
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer
Clinical Cancer Research · 2012 · 187 citations
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal…
Journal of Clinical Oncology · 2023 · 183 citations

Rima Patel
13 papers · 13 as a fellow
BZ
Brittney Zimmerman
9 papers · 5 as a fellow
Dawn Hershman
8 papers
KC
Krystal Cascetta
8 papers
Joseph Sparano
7 papers
JB
Julia Blanter
7 papers · 6 as a resident
Linda Vahdat
7 papers
CH
Charles Hesdorffer
6 papers
DS
David Savage
6 papers
FM
Franco Muggia
6 papers
Karen Antman
6 papers
AB
Aarti Bhardwaj
5 papers · 1 as a fellow

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $19.2K · New York University School of Medicine
2005–2009
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $745.4K · Columbia University Health Sciences
1997–2002

Clinical trials

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Icahn School of Medicine at Mount Sinai
2024–2032
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Icahn School of Medicine at Mount Sinai
2021–2028
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Principal investigator · Withdrawn · Phase 2
Icahn School of Medicine at Mount Sinai
2020–2023
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Principal investigator · Completed · Phase 1
Amy Tiersten
2018–2020